Antiplatelet agents for chronic kidney disease
P Natale, SC Palmer, VM Saglimbene… - Cochrane Database …, 2022 - cochranelibrary.com
Background Antiplatelet agents are widely used to prevent cardiovascular events. The risks
and benefits of antiplatelet agents may be different in people with chronic kidney disease …
and benefits of antiplatelet agents may be different in people with chronic kidney disease …
[HTML][HTML] Anticoagulation in patients with end-stage renal disease and atrial fibrillation: confusion, concerns and consequences
End-stage renal disease (ESRD) patients have a higher prevalence of diabetes mellitus,
hypertension, congestive heart failure and advanced age, along with an increased …
hypertension, congestive heart failure and advanced age, along with an increased …
Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update
Dialysis patients manifest both an increased thrombotic risk and a haemorrhagic tendency.
A great number of patients with chronic kidney disease requiring dialysis have …
A great number of patients with chronic kidney disease requiring dialysis have …